Japan College of Rheumatology guideline for the use of methotrexate in patients with rheumatoid arthritis

Methotrexate (MTX), the anchor drug in the current treatment strategy for rheumatoid arthritis (RA), was first approved for treatment of RA in Japan in 1999 at the recommended dose of 6-8 mg/week; it was approved as first-line drug with the maximum dose of 16 mg/week in February 2011. However, more...

Full description

Saved in:
Bibliographic Details
Published in:Modern rheumatology 2019-01, Vol.29 (1), p.31-40
Main Authors: Kameda, Hideto, Fujii, Takao, Nakajima, Ayako, Koike, Ryuji, Sagawa, Akira, Kanbe, Katsuaki, Tomita, Tetsuya, Harigai, Masayoshi, Suzuki, Yasuo
Format: Article
Language:English
Subjects:
Guideline
Japan College of Rheumatology
methotrexate
rheumatoid arthritis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c437t-1d4566745d29b52a71b314dfee5ad5ba2a6825bd955a1de21aa0c8f3aa33762e3
cites cdi_FETCH-LOGICAL-c437t-1d4566745d29b52a71b314dfee5ad5ba2a6825bd955a1de21aa0c8f3aa33762e3
container_end_page 40
container_issue 1
container_start_page 31
container_title Modern rheumatology
container_volume 29
creator Kameda, Hideto
Fujii, Takao
Nakajima, Ayako
Koike, Ryuji
Sagawa, Akira
Kanbe, Katsuaki
Tomita, Tetsuya
Harigai, Masayoshi
Suzuki, Yasuo
description Methotrexate (MTX), the anchor drug in the current treatment strategy for rheumatoid arthritis (RA), was first approved for treatment of RA in Japan in 1999 at the recommended dose of 6-8 mg/week; it was approved as first-line drug with the maximum dose of 16 mg/week in February 2011. However, more than half of Japanese patients with RA are unable to tolerate a dose of 16 mg/week of MTX. Moreover, some serious adverse events during the treatment with MTX, such as pneumocystis pneumonia (PCP) and lymphoproliferative disorders (LPD) have been observed much more frequently in Japan than in other countries. Therefore, this article, an abridged English translation summarizing the 2016 update of the Japan College of Rheumatology (JCR) guideline for the use of MTX in Japanese patients with RA, is not intended to be valid for global use; however, it is helpful for the Japanese community of rheumatology and its understanding might be useful to the global community of rheumatology.
doi_str_mv 10.1080/14397595.2018.1472358
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1080_14397595_2018_1472358</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2034286661</sourcerecordid><originalsourceid>FETCH-LOGICAL-c437t-1d4566745d29b52a71b314dfee5ad5ba2a6825bd955a1de21aa0c8f3aa33762e3</originalsourceid><addsrcrecordid>eNp9kE1r3DAQhkVJadK0P6FBx152qw9Lsm8JS_pFoFDasxhb47WKbG0kmXT_fbzd3R5zmmF43nfgIeQDZ2vOavaJV7IxqlFrwXi95pURUtWvyNXhvjKaNRfnfYEuyduc_zAmVVM3b8ilaAyvTaWviP8OO5joJoaAW6Sxpz8HnEcoMcTtnm5n7zD4CWkfEy0D0jn_o0YsQywJ_0JB6ie6g-JxKpk--TLQdOrwjkIqQ_LF53fkdQ8h4_vTvCa_P9__2nxdPfz48m1z97DqKmnKirtKaW0q5UTTKgGGt5JXrkdU4FQLAnQtVOsapYA7FByAdXUvAaQ0WqC8Jh-PvbsUH2fMxY4-dxgCTBjnbAWTlai11nxB1RHtUsw5YW93yY-Q9pYze7Bsz5btwbI9WV5yN6cXczui-586a12A2yPgp8XbCE8xBWcL7ENMfYKp89nKl388A9w4jdY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2034286661</pqid></control><display><type>article</type><title>Japan College of Rheumatology guideline for the use of methotrexate in patients with rheumatoid arthritis</title><source>Oxford Journals Online</source><creator>Kameda, Hideto ; Fujii, Takao ; Nakajima, Ayako ; Koike, Ryuji ; Sagawa, Akira ; Kanbe, Katsuaki ; Tomita, Tetsuya ; Harigai, Masayoshi ; Suzuki, Yasuo</creator><creatorcontrib>Kameda, Hideto ; Fujii, Takao ; Nakajima, Ayako ; Koike, Ryuji ; Sagawa, Akira ; Kanbe, Katsuaki ; Tomita, Tetsuya ; Harigai, Masayoshi ; Suzuki, Yasuo ; Japan College of Rheumatology subcommittee on the guideline for the use of methotrexate in patients with rheumatoid arthritis ; Japan College of Rheumatology subcommittee on the guideline for the use of methotrexate in patients with rheumatoid arthritis</creatorcontrib><description>Methotrexate (MTX), the anchor drug in the current treatment strategy for rheumatoid arthritis (RA), was first approved for treatment of RA in Japan in 1999 at the recommended dose of 6-8 mg/week; it was approved as first-line drug with the maximum dose of 16 mg/week in February 2011. However, more than half of Japanese patients with RA are unable to tolerate a dose of 16 mg/week of MTX. Moreover, some serious adverse events during the treatment with MTX, such as pneumocystis pneumonia (PCP) and lymphoproliferative disorders (LPD) have been observed much more frequently in Japan than in other countries. Therefore, this article, an abridged English translation summarizing the 2016 update of the Japan College of Rheumatology (JCR) guideline for the use of MTX in Japanese patients with RA, is not intended to be valid for global use; however, it is helpful for the Japanese community of rheumatology and its understanding might be useful to the global community of rheumatology.</description><identifier>ISSN: 1439-7595</identifier><identifier>EISSN: 1439-7609</identifier><identifier>DOI: 10.1080/14397595.2018.1472358</identifier><identifier>PMID: 29718746</identifier><language>eng</language><publisher>United States: Taylor &amp; Francis</publisher><subject>Guideline ; Japan College of Rheumatology ; methotrexate ; rheumatoid arthritis</subject><ispartof>Modern rheumatology, 2019-01, Vol.29 (1), p.31-40</ispartof><rights>2018 Japan College of Rheumatology. Published by Informa UK Limited, trading as Taylor &amp; Francis Group. 2018</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c437t-1d4566745d29b52a71b314dfee5ad5ba2a6825bd955a1de21aa0c8f3aa33762e3</citedby><cites>FETCH-LOGICAL-c437t-1d4566745d29b52a71b314dfee5ad5ba2a6825bd955a1de21aa0c8f3aa33762e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29718746$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kameda, Hideto</creatorcontrib><creatorcontrib>Fujii, Takao</creatorcontrib><creatorcontrib>Nakajima, Ayako</creatorcontrib><creatorcontrib>Koike, Ryuji</creatorcontrib><creatorcontrib>Sagawa, Akira</creatorcontrib><creatorcontrib>Kanbe, Katsuaki</creatorcontrib><creatorcontrib>Tomita, Tetsuya</creatorcontrib><creatorcontrib>Harigai, Masayoshi</creatorcontrib><creatorcontrib>Suzuki, Yasuo</creatorcontrib><creatorcontrib>Japan College of Rheumatology subcommittee on the guideline for the use of methotrexate in patients with rheumatoid arthritis</creatorcontrib><creatorcontrib>Japan College of Rheumatology subcommittee on the guideline for the use of methotrexate in patients with rheumatoid arthritis</creatorcontrib><title>Japan College of Rheumatology guideline for the use of methotrexate in patients with rheumatoid arthritis</title><title>Modern rheumatology</title><addtitle>Mod Rheumatol</addtitle><description>Methotrexate (MTX), the anchor drug in the current treatment strategy for rheumatoid arthritis (RA), was first approved for treatment of RA in Japan in 1999 at the recommended dose of 6-8 mg/week; it was approved as first-line drug with the maximum dose of 16 mg/week in February 2011. However, more than half of Japanese patients with RA are unable to tolerate a dose of 16 mg/week of MTX. Moreover, some serious adverse events during the treatment with MTX, such as pneumocystis pneumonia (PCP) and lymphoproliferative disorders (LPD) have been observed much more frequently in Japan than in other countries. Therefore, this article, an abridged English translation summarizing the 2016 update of the Japan College of Rheumatology (JCR) guideline for the use of MTX in Japanese patients with RA, is not intended to be valid for global use; however, it is helpful for the Japanese community of rheumatology and its understanding might be useful to the global community of rheumatology.</description><subject>Guideline</subject><subject>Japan College of Rheumatology</subject><subject>methotrexate</subject><subject>rheumatoid arthritis</subject><issn>1439-7595</issn><issn>1439-7609</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>0YH</sourceid><recordid>eNp9kE1r3DAQhkVJadK0P6FBx152qw9Lsm8JS_pFoFDasxhb47WKbG0kmXT_fbzd3R5zmmF43nfgIeQDZ2vOavaJV7IxqlFrwXi95pURUtWvyNXhvjKaNRfnfYEuyduc_zAmVVM3b8ilaAyvTaWviP8OO5joJoaAW6Sxpz8HnEcoMcTtnm5n7zD4CWkfEy0D0jn_o0YsQywJ_0JB6ie6g-JxKpk--TLQdOrwjkIqQ_LF53fkdQ8h4_vTvCa_P9__2nxdPfz48m1z97DqKmnKirtKaW0q5UTTKgGGt5JXrkdU4FQLAnQtVOsapYA7FByAdXUvAaQ0WqC8Jh-PvbsUH2fMxY4-dxgCTBjnbAWTlai11nxB1RHtUsw5YW93yY-Q9pYze7Bsz5btwbI9WV5yN6cXczui-586a12A2yPgp8XbCE8xBWcL7ENMfYKp89nKl388A9w4jdY</recordid><startdate>20190102</startdate><enddate>20190102</enddate><creator>Kameda, Hideto</creator><creator>Fujii, Takao</creator><creator>Nakajima, Ayako</creator><creator>Koike, Ryuji</creator><creator>Sagawa, Akira</creator><creator>Kanbe, Katsuaki</creator><creator>Tomita, Tetsuya</creator><creator>Harigai, Masayoshi</creator><creator>Suzuki, Yasuo</creator><general>Taylor &amp; Francis</general><scope>0YH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20190102</creationdate><title>Japan College of Rheumatology guideline for the use of methotrexate in patients with rheumatoid arthritis</title><author>Kameda, Hideto ; Fujii, Takao ; Nakajima, Ayako ; Koike, Ryuji ; Sagawa, Akira ; Kanbe, Katsuaki ; Tomita, Tetsuya ; Harigai, Masayoshi ; Suzuki, Yasuo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c437t-1d4566745d29b52a71b314dfee5ad5ba2a6825bd955a1de21aa0c8f3aa33762e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Guideline</topic><topic>Japan College of Rheumatology</topic><topic>methotrexate</topic><topic>rheumatoid arthritis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kameda, Hideto</creatorcontrib><creatorcontrib>Fujii, Takao</creatorcontrib><creatorcontrib>Nakajima, Ayako</creatorcontrib><creatorcontrib>Koike, Ryuji</creatorcontrib><creatorcontrib>Sagawa, Akira</creatorcontrib><creatorcontrib>Kanbe, Katsuaki</creatorcontrib><creatorcontrib>Tomita, Tetsuya</creatorcontrib><creatorcontrib>Harigai, Masayoshi</creatorcontrib><creatorcontrib>Suzuki, Yasuo</creatorcontrib><creatorcontrib>Japan College of Rheumatology subcommittee on the guideline for the use of methotrexate in patients with rheumatoid arthritis</creatorcontrib><creatorcontrib>Japan College of Rheumatology subcommittee on the guideline for the use of methotrexate in patients with rheumatoid arthritis</creatorcontrib><collection>Taylor &amp; Francis</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Modern rheumatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kameda, Hideto</au><au>Fujii, Takao</au><au>Nakajima, Ayako</au><au>Koike, Ryuji</au><au>Sagawa, Akira</au><au>Kanbe, Katsuaki</au><au>Tomita, Tetsuya</au><au>Harigai, Masayoshi</au><au>Suzuki, Yasuo</au><aucorp>Japan College of Rheumatology subcommittee on the guideline for the use of methotrexate in patients with rheumatoid arthritis</aucorp><aucorp>Japan College of Rheumatology subcommittee on the guideline for the use of methotrexate in patients with rheumatoid arthritis</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Japan College of Rheumatology guideline for the use of methotrexate in patients with rheumatoid arthritis</atitle><jtitle>Modern rheumatology</jtitle><addtitle>Mod Rheumatol</addtitle><date>2019-01-02</date><risdate>2019</risdate><volume>29</volume><issue>1</issue><spage>31</spage><epage>40</epage><pages>31-40</pages><issn>1439-7595</issn><eissn>1439-7609</eissn><abstract>Methotrexate (MTX), the anchor drug in the current treatment strategy for rheumatoid arthritis (RA), was first approved for treatment of RA in Japan in 1999 at the recommended dose of 6-8 mg/week; it was approved as first-line drug with the maximum dose of 16 mg/week in February 2011. However, more than half of Japanese patients with RA are unable to tolerate a dose of 16 mg/week of MTX. Moreover, some serious adverse events during the treatment with MTX, such as pneumocystis pneumonia (PCP) and lymphoproliferative disorders (LPD) have been observed much more frequently in Japan than in other countries. Therefore, this article, an abridged English translation summarizing the 2016 update of the Japan College of Rheumatology (JCR) guideline for the use of MTX in Japanese patients with RA, is not intended to be valid for global use; however, it is helpful for the Japanese community of rheumatology and its understanding might be useful to the global community of rheumatology.</abstract><cop>United States</cop><pub>Taylor &amp; Francis</pub><pmid>29718746</pmid><doi>10.1080/14397595.2018.1472358</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1439-7595
ispartof Modern rheumatology, 2019-01, Vol.29 (1), p.31-40
issn 1439-7595
1439-7609
language eng
recordid cdi_crossref_primary_10_1080_14397595_2018_1472358
source Oxford Journals Online
subjects Guideline
Japan College of Rheumatology
methotrexate
rheumatoid arthritis
title Japan College of Rheumatology guideline for the use of methotrexate in patients with rheumatoid arthritis
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T12%3A20%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Japan%20College%20of%20Rheumatology%20guideline%20for%20the%20use%20of%20methotrexate%20in%20patients%20with%20rheumatoid%20arthritis&rft.jtitle=Modern%20rheumatology&rft.au=Kameda,%20Hideto&rft.aucorp=Japan%20College%20of%20Rheumatology%20subcommittee%20on%20the%20guideline%20for%20the%20use%20of%20methotrexate%20in%20patients%20with%20rheumatoid%20arthritis&rft.date=2019-01-02&rft.volume=29&rft.issue=1&rft.spage=31&rft.epage=40&rft.pages=31-40&rft.issn=1439-7595&rft.eissn=1439-7609&rft_id=info:doi/10.1080/14397595.2018.1472358&rft_dat=%3Cproquest_cross%3E2034286661%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c437t-1d4566745d29b52a71b314dfee5ad5ba2a6825bd955a1de21aa0c8f3aa33762e3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2034286661&rft_id=info:pmid/29718746&rfr_iscdi=true